Localization of Drug Release Sites from an Oral Sustained‐Release Formulation of 5‐ASA (Pentasa®) in the Gastrointestinal Tract Using Gamma Scintigraphy

The Journal of Clinical Pharmacology

Volumn 33, Issue 8, 1993, Pages 712-718

  Hardy, J G ^a   Harvey, W J ^b   Sparrow, R A ^a   Marshall, G B ^b   Steed, K P ^a   Macarios, M ^b   Wilding, I R ^a  

^a PHARMACEUTICAL PROFILES LTD   (United Kingdom)

^b Nordic Merrell Dow Research   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE;

ADULT; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG RELEASE; FEMALE; GASTROINTESTINAL TRACT; HUMAN; HUMAN EXPERIMENT; MALE; SCINTIGRAPHY; SCINTILLATION CAMERA; SMALL INTESTINE;

ADMINISTRATION, ORAL; ADULT; AMINOSALICYLIC ACIDS; DELAYED-ACTION PREPARATIONS; FEMALE; GASTROINTESTINAL SYSTEM; HUMAN; MALE; MESALAMINE; STOMACH; TIME FACTORS;

EID: 0027203919     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1993.tb05612.x     Document Type: Article

References (26)

1. An experiment to determine the active therapeutic moiety of sulphasalazine
2. Distribution studies of salicylazosulfapyridine and its metabolites
3. Kinetics of 5‐aminosalicylic acid after jejunal installation in man
4. Absorption, metabolism and excretion of salicylazosulfapyridine in man
5. Acetylation of 5‐aminosalicylic acid by human colonic epithelial cells
6. The pharmacokinetics of olsalazine sodium in healthy volunteers after a single IV dose and after oral doses with and without food
7. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double blind comparison with sulphasalazide
8. An oral preparation to release drugs in the human colon
9. A new slow‐release form of 5‐aminosalicylic acid for the treatment of inflammatory bowel disease. Biopharmaceutical and clinical pharmacokinetic characteristics
10. 5‐aminosalicylic acid in a slow release preparation: Bioavailability plasma level and excretion in humans
11. Evaluations of an enteric coated, delay‐release 5‐ASA tablet in patients with inflammatory bowel disease
12. GI tract conditions and topical/systemic availability of 5‐aminosalicylic acid in a slow release preparation (Pentasa®)
13. Gastrointestinal behavior of orally administered radiolabeled erythromycin pellets in man as determined by gamma scintigraphy
14. Evaluation of an enteric‐coated naproxen pellet formulation
15. Characterization of the in vivo behavior of a controlled release formulation of levodopa (Sinemet CR)
16. 15N‐labelled drug to healthy volunteers
17. Gastrointestinal transit and systemic absorption of captopril from a pulsed release formulation
18. The effect of food on the in vivo behavior of a novel sustained release formulation of tiaprofenic acid
19. Validity of the geometric mean correction in the quantification of whole bowel transit
20. Assay of 5‐aminosalicylate and its acetylated metabolite in biological fluids by high performance liquid chromatography
21. Response of Crohn's disease to oral Pentasa: Results of a multicentre study
22. Induction of remission in ulcerative colitis with oral mesalamine capsules (Pentasa)
23. Double blind comparison of 5‐ASA and acetyl‐5‐ASA suppositories in patients with idiopathic proctitis
24. Gastrointestinal pH profiles in ulcerative colitis
25. Gastrointestinal transit of a multiparticulate tablet formulation in patients with active ulcerative colitis
26. Release of 5‐ASA from Pentasa during normal and accelerated intestinal transport time